{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"MTD is defined as the highest tested dose of LMB-100 and SEL-110 at which no more than 1 of 6 subjects experience a dose limiting toxicity. A dose limiting toxicity is defined as any of the following: Grade 4 neutropenia for a minimum duration of 7 days. Grade 4 thrombocytopenia (≤25.0 x 10(9) cells/L), Grade 3 thrombocytopenia associated with bleeding episodes, and Grade 4 anemia. Grade ≥3 non-hematological toxicity with the exception of Alopecia (any grade), Grade 3 nausea and vomiting lasting \\> 48 hours despite appropriate treatment, Grade 3 diarrhea lasting for ≤ 2 days with no fever or dehydration, and laboratory values of ≥ grade 3 that are judged not clinically significant by the investigator. Any other drug related toxicity considered significant enough to be qualified as a DLT in the opinion of the principal investigator. Inability to start cycle 2 within 3 weeks after completing cycle 1 due to drug-related adverse events.","groups":[{"description":"Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses\n\nLMB-100: administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles\n\nSEL-110: administered on day 1 of each cycle for up to 4 cycles","id":"OG000","title":"1/Dose Escalation"}],"populationDescription":"MTD was not found because the study was closed due to a fatal occurrence of pneumonitis that was attributed to one of the study drugs.","reportingStatus":"POSTED","timeFrame":"Day 21","title":"Maximum Tolerated Dose (MTD)","type":"PRIMARY"}